There is no cure for myeloproliferative neoplasms, and the goals of treatment are to control peripheral blood counts, adequately control disease-related symptoms, reduce the risk of thrombosis-hemorrhage, and delay progression to leukemia. Neither PV nor ET prognostic score includes symptoms: International Prognostic Scoring System for ET (IPSET): based on white blood cell count ≥ 11 × 109/L (1 point); age ≥ 60 years (2 points); history of thrombosis (1 point) is classified as low risk 0, intermediate risk 1-2 points with median survival of 24.5 years; high risk 3-4 points with median survival of 13.8 years. PV International Working Group on Myeloproliferative Tumors Research and Treatment (IWG-MRT): based on white blood cell count ≥ 15 × 109/L (1 point); deep vein thrombosis (1 point); age 57-66 years (2 points) and age ≥ 67 years (5 points); classified as low risk 0 points, median survival 26 years, intermediate risk 1-2 points, median survival 15 years; high risk ≥ 3 points, median survival 8.3 years. Only MF focused on symptoms, MF International Prognostic Score System (DIPSS): age, hemoglobin, leukocytes, peripheral blood primitive cells, systemic symptoms. Score low-risk OS not reached; intermediate-risk-1 14.2 years; intermediate-risk-2 4 years; high-risk 1.5 years.